SCHEDULE 13G/A: Harvey Partners Discloses 4.96% Passive Stake in Harvard Bioscience Inc.
Beneficial Ownership Disclosure
Investment firm Harvey Partners, LLC has filed an amended Schedule 13G, reporting a 4.96% beneficial ownership stake in Harvard Bioscience Inc. as of March 31, 2025.
Summary
- Harvey Partners, LLC, a Delaware limited liability company, has filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Harvard Bioscience Inc.
- As of March 31, 2025, Harvey Partners, LLC beneficially owned 2,187,500 shares of Harvard Bioscience Inc. Common Stock.
- This ownership represents 4.96% of the Company's Common Stock outstanding, based on 44,074,475 shares outstanding as of March 5, 2025, as reported in the Company's Form 10-K.
- The Reporting Person, Harvey Partners, LLC, is an investment manager for Harvey SMidCap Fund, LP and Harvey QP, LP, and also holds shares in managed accounts.
- James A. Schwartz and Jeffrey C. Moskowitz, Managing Members of Harvey Partners, LLC, share voting and investment power over these securities.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter the company's sentiment, as it indicates a passive, ordinary course investment.
Positives
- The filing indicates that an investment firm, Harvey Partners, LLC, holds a significant, albeit passive, stake in Harvard Bioscience Inc., which can be viewed as a vote of confidence in the company's long-term prospects.
- The certification explicitly states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a stable, non-activist investment.
Negatives
- The document is a routine regulatory disclosure of ownership and does not contain information that would be considered negative regarding Harvard Bioscience Inc.'s operations or financial performance.
Risks
- The document itself does not detail specific risks related to Harvard Bioscience Inc.'s business or operations; it is solely a disclosure of beneficial ownership.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Harvard Bioscience Inc.'s future outlook.
Industry Context
This filing is a standard regulatory disclosure for passive investors in publicly traded companies. It reflects an investment firm's stake in a life sciences company, which is a common occurrence in the investment landscape. The filing itself does not provide specific insights into broader industry trends or competitive dynamics beyond the ownership structure.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, albeit passive, ownership stake held by an investment firm, which can inform their understanding of the company's investor base.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date as of which Harvard Bioscience Inc. reported 44,074,475 shares of Common Stock outstanding in its Annual Report on Form 10-K. |
| 03/14/2025 | Date Harvard Bioscience Inc. filed its Annual Report on Form 10-K with the SEC. |
| 03/31/2025 | Date of event which required the filing of this Schedule 13G Amendment No. 2, reflecting the beneficial ownership stake. |
| 05/15/2025 | Date the Schedule 13G Amendment No. 2 was signed and filed by Harvey Partners, LLC. |
Keywords
Harvard Bioscience Inc., Harvey Partners LLC, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Adviser, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.